| Old Articles: <Older 6741-6750 Newer> |
|---|
 |
InternetNews
April 11, 2005
Colin C. Haley |
MCI Shareholders: Verizon's Slim Deal Sounds Shady Some shareholders are upset that Mexican billionaire Carlos Slim Helu is receiving a higher price for his MCI shares than they are.   |
The Motley Fool
April 11, 2005
Rich Smith |
Make Wall Street Your Bank Despite the stock market's renewed popularity since its recent 2003 lows, studies show that as many as 50% of American households still don't own stocks -- not so much as an S&P 500 index fund. These people can do better. |
The Motley Fool
April 11, 2005
Alyce Lomax |
Overstock's Secret Weapon Maybe, just maybe, the online outlet heavyweight is on an Odyssey toward greatness. Investors, take note. |
The Motley Fool
April 11, 2005
Rich Smith |
Ford Fesses Up Automaker recants on 2005 profits target. Investors, take note. |
The Motley Fool
April 8, 2005
Jeremy MacNealy |
No Swimming Off Pier 1 Pier 1 caps off a difficult year. Be careful diving into these dangerous waters. |
The Motley Fool
April 8, 2005
Stephen D. Simpson |
Abbott Hopes to Maxx Out Abbott announced FDA approval to begin a pivotal trial for its drug-eluting stent. Will this be too little too late for shareholders, or a true dark horse? |
The Motley Fool
April 8, 2005
W.D. Crotty |
Turning Blue Coat Inside Out The SEC begins a formal investigation into disclosures at the company that "enables organizations to keep 'good' employees from doing 'bad' things on the Internet." Somewhat ironic. |
The Motley Fool
April 8, 2005
Dan Bloom |
A Fashion Faux Pas? Christopher and Banks continues to struggle with its fashion mix, to put it mildly. With a P/E of around 24 based on trailing 12-month earnings, the stock doesn't appear to offer much of a margin of safety. |
The Motley Fool
April 8, 2005
David Nierengarten |
The Psoriasis Wars Continue Biogen-Idec hopes its new drug will conquer the lucrative psoriasis market. Investors should consider taking a second look at the company's prospects. |
The Motley Fool
April 8, 2005
Stephen D. Simpson |
Accenture-ating the Positive One of the biggest names in consulting disappoints the Street. But should investors be upset? |
| <Older 6741-6750 Newer> Return to current articles. |
